0001870940-26-000011
SEC filingFY2025 marked by 15.8% revenue decline to $151.8M and operating loss expansion to -$11.6M due to unleveraged fixed costs amid fewer cases, though capex discipline generated $692K free cash flow supporting restructuring.
Revenue fell 15.8% year-over-year to $151.8M in FY2025 from $180.3M, primarily due to decreased case volume compared to 2024. The business context explains that in the aesthetic market, consumer preferences shift rapidly, and failure to adapt service offerings, centers, or pricing can materially reduce demand. This volume drop directly impacted cost of service, which decreased in absolute terms but increased as a percentage of revenue because fixed costs such as rent and nursing expenses could not be leveraged or scaled down proportionally. With centers employing an average of approximately 10 full-time equivalent employees each—varying by size, case volume, and types—this high-fixed-cost model exposed operational inflexibility, driving the operating margin to -7.6%. Investors should note management's focus on optimizing marketing investments to enhance efficiency, improve return on investment, and achieve sustainable revenue growth, as this addresses the core demand weakness.
Net cash from operating activities declined to $3.1M from $11.4M, reflecting profitability pressures and working capital shifts tied to lower cases. However, capital expenditures dropped significantly to $2.4M from $14.0M, yielding $692K in free cash flow. This preservation tactic aligns with the operating model's potential for capital-efficient growth, allowing focus on restructuring without liquidity strain. The London closure costs represent a deliberate portfolio optimization, while marketing refinements aim to rebuild case momentum. Risks persist, as new centers may underperform planned growth, per risk factors, but current discipline supports platform scalability for future free cash flow generation.